Literature DB >> 7310225

Rapid in vivo clearance of C5ades arg: a possible protective mechanism against complement-mediated tissue injury.

D J Weisdorf, D E Hammerschmidt, H S Jacob, P R Craddock.   

Abstract

C5ades arg is an important mediator of the tissue injury associated with intravascular complement activation and exerts its effects by causing granulocyte aggregation, leukoembolism, and oxidative damage to endothelial cells. We have now investigated some of the mechanisms responsible for deactivation of this potent complement fragment by studying the clearance of C5ades arg from the plasma of New Zealand white rabbits in vivo. Quantitative aggregation of human granulocytes was used as a bioassay for rabbit C5ades arg. After a bolus intravenous infusion of activated autologous plasma complement, athe plasma C5ades arg content peaked within 60 sec and was cleared rapidly and exponentially, with a mean half-life of 3.0 +/- 0.6 (S.E.M.) min. In neutropenic animals the half-life of C5ades arg was prolonged by 57% +/- 22 and splenectomy, but not hepatectomy, also significantly lengthened the half-life by 48% +/- 18. The most striking delay in C5ades arg clearance was induced by inhibition of endogenous proteases with EACA and aprotinin, which prolonged the half-life by 87% +/- 4 and 94% +/- 12, respectively. These data demonstrate that like other complement fragments such as C3a, C5ades arg has a very brief functional half-life in experimental animals and that although other mechanisms may be operative, endogenous proteases, circulating granulocytes, and the spleen may be important in deactivating this biologically important complement fragment. Impairment of these and other clearance mechanisms could lead to prolonged and excessive complement activation and subsequent exaggerated tissue injury.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7310225

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  11 in total

1.  Classical complement pathway activation in the nasal tissue of patients with chronic rhinosinusitis.

Authors:  Griet A Van Roey; Christopher C Vanison; Jeffanie Wu; Julia H Huang; Lydia A Suh; Roderick G Carter; James E Norton; Stephanie Shintani-Smith; David B Conley; Kevin C Welch; Anju T Peters; Leslie C Grammer; Kathleen E Harris; Kathryn E Hulse; Atsushi Kato; Whitney W Stevens; Robert C Kern; Robert P Schleimer; Bruce K Tan
Journal:  J Allergy Clin Immunol       Date:  2016-12-12       Impact factor: 10.793

2.  Defining the complement biomarker profile of C3 glomerulopathy.

Authors:  Yuzhou Zhang; Carla M Nester; Bertha Martin; Mikkel-Ole Skjoedt; Nicole C Meyer; Dingwu Shao; Nicolò Borsa; Yaseelan Palarasah; Richard J H Smith
Journal:  Clin J Am Soc Nephrol       Date:  2014-10-23       Impact factor: 8.237

3.  Complement activation in patients with renal failure as detected through the quantitation of fragments of the complement proteins C3, C5, and factor B.

Authors:  M Oppermann; M Haubitz; E Quentin; O Götze
Journal:  Klin Wochenschr       Date:  1988-09-15

4.  In vivo clearance and tissue distribution of C5a and C5a des arginine complement fragments in rabbits.

Authors:  R O Webster; G L Larsen; P M Henson
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

5.  Generation of chemotactic activity in serum by Haemophilus influenzae type b.

Authors:  M F Tosi; S L Kaplan; E O Mason; G J Buffone; D C Anderson
Journal:  Infect Immun       Date:  1984-02       Impact factor: 3.441

6.  Plasma clearance of the human C5a anaphylatoxin by binding to leucocyte C5a receptors.

Authors:  M Oppermann; O Götze
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

7.  In vivo clearance studies of the terminal fluid-phase complement complex in rabbits.

Authors:  F Hugo; C Berstecher; S Krämer; W Fassbender; S Bhakdi
Journal:  Clin Exp Immunol       Date:  1989-07       Impact factor: 4.330

8.  Complement activation in septic baboons detected by neoepitope-specific assays for C3b/iC3b/C3c, C5a and the terminal C5b-9 complement complex (TCC).

Authors:  T E Mollnes; H Redl; K Høgåsen; A Bengtsson; P Garred; L Speilberg; T Lea; M Oppermann; O Götze; G Schlag
Journal:  Clin Exp Immunol       Date:  1993-02       Impact factor: 4.330

9.  The human complement fragment receptor, C5L2, is a recycling decoy receptor.

Authors:  Anne-Marie Scola; Kay-Ole Johswich; B Paul Morgan; Andreas Klos; Peter N Monk
Journal:  Mol Immunol       Date:  2008-12-18       Impact factor: 4.407

10.  Stimulation of neutrophil functions by C5a(desArg): an in vitro model of haemodialysis.

Authors:  I Eckle; G Kolb; E M Martin; K Havemann
Journal:  Mediators Inflamm       Date:  1992       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.